Sign in
Taking people in United StatesPhase 1

Tests CLSP-1025 in adults with solid tumors carrying the p53 R175H mutation

Tests CLSP-1025 in adults with advanced solid tumors carrying a p53 mutation.

Key facts

Who runs it
Clasp Therapeutics, Inc.
Where
Baltimore, Chicago, Dallas, Durham, Hackensack, Houston, Lexington, Los Angeles, Miami, Nashville, New York, Philadelphia, Sacramento, San Francisco, Scottsdale, Seattle, and Tucson, United StatesSee the 21 sites
Trial code
Registry title
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Status
Recruiting
Phase
Phase 1
People taking part
90 people, planned
Started
28 Feb 2025
Expected to end
Jun 2028
Type of study
Interventional, 2 groups
Treatments tested
  • CLSP-1025
Record updated
13 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or spread solid tumors that carry the TP53 R175H change and who are HLA-A*02:01 positive. It tests a new drug, CLSP-1025.

Age
18 years or older
Sex
All sexes can join
Disease stage
Locally advanced or metastatic solid tumor that got worse after standard treatment, or for which no standard treatment exists. Performance status (ECOG) of 0 to 1.
Earlier treatment
Must have had standard of care therapy that stopped working, or have no standard therapy available. Must not have had other p53 R175H-directed therapies. Must have recovered from side effects of earlier cancer treatment.
Biomarker or test result
Tumor must have the TP53 R175H variant mutation, confirmed by an accredited laboratory test. Must be HLA-A*02:01 positive by central assay.

Main reasons for not taking part

  • Li-Fraumeni syndrome or other known germline p53 R175H mutation
  • Active infection needing systemic antimicrobial treatment
  • Another primary cancer within the 2 years before enrollment (with a few exceptions)
  • Known active brain or spinal cord spread of cancer, or carcinomatous meningitis
  • Not fully recovered from side effects of earlier cancer treatment

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients must be at least 18 years of age at the time of signing the informed consent
  • Patients must be willing and able to provide written informed consent
  • Patients must have locally advanced or metastatic solid tumors that have progressed after standard of care therapy or for which no standard therapy exists
  • Tumors must harbor a TP53 R175H variant mutation confirmed by an accredited laboratory-based test
  • Patients must be HLA-A*02:01 positive by central assay
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the time of enrollment
  • Adequate hematological, renal and hepatic function
  • Per Investigator judgement, patient is willing and able to complete study visits and/or procedures per the protocol and comply with study requirements for study participation

Who cannot take part

  • Patients who have received other p53 R175H-directed therapies
  • Patients who have not fully recovered from adverse events due to previous anticancer therapies
  • Any other primary malignancy within the 2 years prior to enrollment (except for non- melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or prostate cancer in remission
  • Patients with Li-Fraumeni syndrome or other known germline p53 R175H mutation
  • Patients with active infection requiring systemic antimicrobial therapy
  • Known active central nervous system metastases and/or carcinomatous meningitis

Where in United States

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterBaltimore, United StatesContact: Lauren Harshman, MDTaking people
  • The University of Chicago Comprehensive Cancer CenterChicago, United StatesContact: Lauren Harshman, MDTaking people
  • Baylor University Medical CenterDallas, United StatesContact: Lauren Harshman, MDTaking people
  • Mary Crowley Cancer ResearchDallas, United StatesContact: Lauren Harshman, MDTaking people
  • Duke Cancer InstituteDurham, United StatesContact: Lauren Harshman, MDTaking people
  • Hackensack University Medical CenterHackensack, United StatesContact: Oncology Clinical Research Referral OfficeTaking people
  • MD Anderson Cancer CenterHouston, United StatesContact: Lauren Harshman, MDTaking people
  • University of Kentucky/Markey Cancer CenterLexington, United StatesContact: Lauren Harshman, MDTaking people
  • USC / Norris Comprehensive Cancer CenterLos Angeles, United StatesContact: Lauren Harshman, MDTaking people
  • University of Miami - Sylvester Comprehensive Cancer CenterMiami, United StatesContact: Lauren Harshman, MDTaking people
  • Sarah Cannon Research Institute (SCRI) Oncology PartnersNashville, United StatesContact: Lauren Harshman, MDTaking people
  • Vanderbilt University Medical CenterNashville, United StatesContact: Lauren Harshman, MDTaking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Lauren Harshman, MDTaking people
  • NYU Langone HealthNew York, United StatesContact: Lauren Harshman, MDTaking people
  • Fox Chase Cancer CenterPhiladelphia, United StatesContact: Lauren Harshman, MDTaking people
  • Thomas Jefferson University, Sidney Kimmel Cancer CenterPhiladelphia, United StatesContact: Aliya RogersTaking people
  • University of California Davis Comprehensive Cancer CenterSacramento, United StatesContact: Lauren Harshman, MDTaking people
  • University of California San FranciscoSan Francisco, United StatesContact: Lauren Harshman, MDTaking people
  • HonorHealth Research InstituteScottsdale, United StatesContact: Lauren Harshman, MDTaking people
  • Fred Hutchinson Cancer CenterSeattle, United StatesContact: Lauren Harshman, MDTaking people
  • The University of Arizona Cancer CenterTucson, United StatesContact: Lauren Harshman, MDTaking people

About the trial

What the trial wants to find out

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

The 2 groups in the trial

  • Part A: Monotherapy Dose Escalation of CLSP-1025Treatment being tested

    Dose escalation of CLSP-1025 in HLA-A\*02:01-positive adult patients with advanced solid tumors that harbor the p53 R175H mutation

    Treatment: CLSP-1025

  • Part B: Monotherapy Dose Expansion of CLSP-1025Treatment being tested

    Dose expansion of CLSP-1025 in HLA-A\*02:01-positive adult patients with advanced solid tumors that harbor the p53 R175H mutation

    Treatment: CLSP-1025

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Plain-language title
Tests CLSP-1025 in adults with solid tumors carrying the p53 R175H mutationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 February 2026